Enabling
technologies

We continue to embrace opportunities that may enable the delivery of potentially transformational medicines.

  • Takeda
    Our collaboration with Takeda Pharmaceuticals aims to accelerate the discovery and development of innovative, first-in-class therapies that address central nervous system (CNS) disorders. As part of this strategic partnership, Takeda has an option to a global 50:50 co-development and co-commercialization profit share for select CNS targets. Takeda will also fund the collaboration’s research to design next generation therapies for additional CNS disorders, including Alzheimer’s and Parkinson’s diseases.
  • Pfizer
    Our Pfizer partnership focuses on developing genetically targeted therapies aimed at silencing the underlying causes of debilitating metabolic disease. The collaboration combines our proprietary stereopure drug development platform, across antisense and RNAi modalities, with GalNAc and Pfizer’s hepatic targeting technology for enhanced delivery to the liver.
  • Readcoor
    Our collaboration with ReadCoor is aimed at developing a cellular map of the mouse brain through in situ transcriptomics. We expect this collaboration will enable a highly detailed characterization of the impact of nucleic acid based therapies in different cell types, across cellular compartments and the role of stereochemistry in optimizing silencing and splicing therapies in the brain.
  • University of Dundee
    Our research collaboration with Dundee investigates the potential of using antisense oligonucleotides as therapeutics for both common and rare skin diseases, including atopic dermatitis and keratin disorders. Aided by Dundee’s proprietary human skin explant model, we aim to discover stereoisomers with superior pharmacological properties that confer therapeutic efficacy through targeted mRNA knockdown or exon skipping and are amenable to topical treatment.